Skip to main content
Top
Published in: Indian Journal of Gastroenterology 6/2015

01-11-2015 | Original Article

Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease

Authors: Hrishikesh Samant, Devendra Desai, Philip Abraham, Anand Joshi, Tarun Gupta, Alpa Dherai, Tester Ashavaid

Published in: Indian Journal of Gastroenterology | Issue 6/2015

Login to get access

Abstract

Introduction

In clinical practice, endoscopic findings are often used for assessing disease activity in inflammatory bowel disease (IBD). In recent years, blood and stool markers are being increasingly used for this purpose. Among them, the fecal calprotectin (FC) level is probably the most favored. Data on the reliability of FC are lacking from countries like India, where gut infections are common.

Objective

The aims of this study were to compare the FC level with the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) as non-invasive markers of IBD and, in patients with ulcerative colitis (UC), and to study its correlation with disease extent, clinical activity, and endoscopic severity.

Methods

Records of patients with IBD who had tests for FC, ESR and CRP and colonoscopy done within a 2-week period, between 2012 and 2014, were retrieved. Sixty-three patients (UC 32, Crohn’s disease [CD] 31) were included for analysis. ESR, CRP and FC were compared to endoscopy to assess inflammation.

Results

Patients with UC had higher levels of FC than those with ileocolonic CD (median FC 800 mcg/g vs. 619 mcg/g, respectively; p = 0.04). FC levels correlated with CRP (r = 0.4, p < 0.001) but not with ESR (r = 0.21, p = 0.09). In patients with UC with endoscopic evidence of inflammation, more (86.9 %) had FC >200 mcg/g (cut-off for disease activity in our laboratory) than had ESR >20 mm in the first hour (60.6 %) or positive CRP (65.6 %) (<0.01); FC levels increased with increasing endoscopic Mayo score (p = 0.001) and Truelove-Witt’s clinical severity score (p = 0.006), but did not correlate with disease extent (p = 0.7). The best FC cut-off level to identify ‘active UC’ (Mayo grade 2 or more) was 800 mcg/g.

Conclusion

Fecal calprotectin level correlates with CRP but not with ESR. In patients with UC with inflammation, FC >200 mcg/g is more often positive than raised ESR or CRP; it also correlates with clinical and endoscopic activity but not with disease extent. FC level >800 mcg/g can be used to differentiate active from inactive UC.
Literature
1.
go back to reference Loftus EV Jr. Clinical perspectives in Crohn’s disease. Objective measures of disease activity: alternatives to symptom indices. Rev Gastroenterol Disord. 2007;7 Suppl 2:S8–16. Loftus EV Jr. Clinical perspectives in Crohn’s disease. Objective measures of disease activity: alternatives to symptom indices. Rev Gastroenterol Disord. 2007;7 Suppl 2:S8–16.
2.
go back to reference Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–5.PubMedCrossRef Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–5.PubMedCrossRef
3.
4.
go back to reference Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis inducing activity. Biol Pharm Bull. 2003;26:753–60.PubMedCrossRef Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis inducing activity. Biol Pharm Bull. 2003;26:753–60.PubMedCrossRef
5.
go back to reference Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450–60.PubMedCrossRef Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450–60.PubMedCrossRef
6.
go back to reference Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364–8.PubMedPubMedCentralCrossRef Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364–8.PubMedPubMedCentralCrossRef
7.
go back to reference Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of fecal calprotectin in pediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467–70.PubMedCrossRef Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of fecal calprotectin in pediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467–70.PubMedCrossRef
8.
go back to reference Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176–80.PubMedCrossRef Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176–80.PubMedCrossRef
9.
go back to reference Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin N Am. 2004;33:235–50.CrossRef Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin N Am. 2004;33:235–50.CrossRef
10.
go back to reference Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516–26.PubMedCrossRef Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516–26.PubMedCrossRef
11.
go back to reference Daperno M, Castiglione F, Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484–98.PubMedCrossRef Daperno M, Castiglione F, Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484–98.PubMedCrossRef
12.
go back to reference Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9–15.PubMedCrossRef Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9–15.PubMedCrossRef
13.
go back to reference Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48–54.PubMedCrossRef Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48–54.PubMedCrossRef
14.
go back to reference Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450–5.PubMedCrossRef Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450–5.PubMedCrossRef
15.
go back to reference Roseth AG. Determination of fecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607–9.PubMedCrossRef Roseth AG. Determination of fecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607–9.PubMedCrossRef
16.
go back to reference Costa F, Mumolo MG, Bellini M, et al. Role of fecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–7.PubMedCrossRef Costa F, Mumolo MG, Bellini M, et al. Role of fecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–7.PubMedCrossRef
17.
go back to reference Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37:85–96.CrossRef Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37:85–96.CrossRef
18.
go back to reference Narayanan MP, Vaidyanathan K, Gajendra O, Shine S, Balakrishna V. Fecal calprotectin in inflammatory bowel diseases. Indian J Clin Biochem. 2009; Suppl 24:1-24 (Abst.). Narayanan MP, Vaidyanathan K, Gajendra O, Shine S, Balakrishna V. Fecal calprotectin in inflammatory bowel diseases. Indian J Clin Biochem. 2009; Suppl 24:1-24 (Abst.).
19.
go back to reference Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–13.CrossRef Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–13.CrossRef
20.
go back to reference Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14:53–7.PubMedPubMedCentralCrossRef Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14:53–7.PubMedPubMedCentralCrossRef
21.
22.
go back to reference Kobelska-Dubiel N, Ignas I, Krauss H, et al. Calprotectin in feces as a marker of inflammatory bowel in children. Pediatr Gastroenterol, Hepatol Child Nutr. 2007;9:172–5. Kobelska-Dubiel N, Ignas I, Krauss H, et al. Calprotectin in feces as a marker of inflammatory bowel in children. Pediatr Gastroenterol, Hepatol Child Nutr. 2007;9:172–5.
23.
go back to reference Canani RB, Terrin G, Rapacciuolo L, et al. Fecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.PubMedCrossRef Canani RB, Terrin G, Rapacciuolo L, et al. Fecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.PubMedCrossRef
24.
go back to reference Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–9.PubMedCrossRef Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–9.PubMedCrossRef
25.
go back to reference Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332–41.PubMedCrossRef Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332–41.PubMedCrossRef
26.
go back to reference De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–7.PubMedCrossRef De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–7.PubMedCrossRef
27.
go back to reference Mooiweer E, Severs M, Schipper ME, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50–5.PubMedCrossRef Mooiweer E, Severs M, Schipper ME, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50–5.PubMedCrossRef
28.
go back to reference Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865–70.PubMedCrossRef Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865–70.PubMedCrossRef
29.
go back to reference Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034–42.PubMedCrossRef Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034–42.PubMedCrossRef
30.
31.
go back to reference Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–82.PubMedCrossRef Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–82.PubMedCrossRef
32.
go back to reference Pezzone MA, Wald A. Functional bowel disorders in inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:347–57.CrossRef Pezzone MA, Wald A. Functional bowel disorders in inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:347–57.CrossRef
33.
go back to reference Ginsburg PM, Bayless TM. Managing functional disturbances in patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2005;8:211–21.PubMedCrossRef Ginsburg PM, Bayless TM. Managing functional disturbances in patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2005;8:211–21.PubMedCrossRef
Metadata
Title
Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease
Authors
Hrishikesh Samant
Devendra Desai
Philip Abraham
Anand Joshi
Tarun Gupta
Alpa Dherai
Tester Ashavaid
Publication date
01-11-2015
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 6/2015
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-015-0608-x

Other articles of this Issue 6/2015

Indian Journal of Gastroenterology 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.